Chimeric antigen receptor T cell therapy for multiple myeloma.
Kana HasegawaNaoki HosenPublished in: Inflammation and regeneration (2019)
Chimeric antigen receptor (CAR) T cell therapy is a new cancer immunotherapy targeting cancer-specific cell surface antigen. CD19-CAR T cells have been already shown to be very effective to B cell leukemia/lymphoma. Now, many researchers are developing CAR T cells for multiple myeloma. CAR T cells targeting B cell maturation antigen (BCMA) showed promising efficacy in early phase clinical trials. We have recently reported that CAR T cells targeting the activated integrin β7 can selectively eradicate MM cells including CD19+ clonotypic B cells and are preparing a clinical trial.
Keyphrases
- clinical trial
- multiple myeloma
- cell therapy
- induced apoptosis
- cell surface
- cell cycle arrest
- cancer therapy
- bone marrow
- endoplasmic reticulum stress
- stem cells
- diffuse large b cell lymphoma
- phase ii
- mesenchymal stem cells
- papillary thyroid
- oxidative stress
- randomized controlled trial
- study protocol
- nk cells
- phase iii
- cell adhesion